

Amaxa™ HT Nucleofector™ protocol for primary mammalian neurons

Cell description

Primary mammalian neurons, primary neurons freshly isolated from embryonic (E18) or neonatal (P1–2) mammalian neural tissues.

Note

Mammalian neurons display significant phenotypic variations due to the wide range of both species and tissues from which they may be sourced. This basic protocol describes how to easily define optimal Nucleofection™ conditions for different mammalian neural cells. We recommend to first test a set of pre-selected Nucleofector™ programs together with the P3 primary cell HT Nucleofector™ kit.

If you have questions regarding your neurons of interest, please contact our scientific support team for further help with the optimization.

Product description

Recommended kits

P3 primary cell HT Nucleofector™ kit

Cat. No.	V5SP-3002
Size (reactions)	2×384
P3 primary cell HT Nucleofector™ solution	22.5 ml
Supplement	5 ml
pmaxGFP™ vector (1 µg/µl in 10 mM Tris pH 8.0)	50 µg
384-well Nucleocuvette™ plate (s)	2

Cat. No.	V5SP-3010
Size (reactions)	10×384
P3 primary cell HT Nucleofector™ solution	90 ml
Supplement	20 ml
pmaxGFP™ vector (1 µg/µl in 10 mM Tris pH 8.0)	150 µg
384-well Nucleocuvette™ plate (s)	10

Storage and stability

Store Nucleofector™ solution, supplement and pmaxGFP™ vector at 4°C. For long term storage pmaxGFP™ vector is ideally stored at -20°C. The expiry date is printed on the solution box. Once the Nucleofector™ supplement is added to the Nucleofector™ solution it is stable for three months at 4°C.

Note

HT Nucleofector™ solutions can only be used with conductive polymer cuvettes, i.e. in the HT Nucleofector™, the 96-well Shuttle™ device and in the 4D-Nucleofector™ system. They are not compatible with the Nucleofector™ II/2b device.

Optimization guidelines

The initial optimization experiment is comprised of 16 reactions: 7 different Nucleofector™ programs are tested in duplicate with 1 Nucleofector™ solution plus 1 control (no program). The HT Nucleofector™ program which turns out to be the most appropriate should be used for all subsequent transfections. A further fine tuning of Nucleofection™ conditions can be performed with the help of our scientific support team.

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17–24
A	CA-138-AA	CL-133-AA	CU-110-AA	DC-100-AA	DC-104-AA	DR-114-AA	EM-110-AA	control	CA-138-AA	CL-133-AA	CU-110-AA	DC-100-AA	DC-104-AA	DR-114-AA	EM-110-AA	control	
B																	
C																	
D																	
E																	
F																	
G																	
H																	
I																	
J																	
K																	
L																	
M																	
N																	
O																	
P																	

Required material

Note

Please make sure that the entire supplement is added to the Nucleofector™ solution.

- HT Nucleofector™ system
- Supplemented Nucleofector™ solution at room temperature
- Supplied 384-well Nucleocuvette™ plates
- Supplied pmaxGFP™ vector, stock solution 1 µg/µl

Note

Volume of substrate solution added to each sample should not exceed 10 % of the total reaction volume (2 µl for 20 µl reactions). For positive control using pmaxGFP™ vector, please dilute the stock solution to reach the appropriate working concentration.

- Substrate of interest, highly purified, preferably by using endotoxin free kits; A260 : A280 ratio should be at least 1.8
- 384-well Nucleocuvette™ plates are best handled with an automated liquid handling system. If manual pipetting is required please use compatible tips: epT.I.P.S.® [US/CDN: Eppendorf North America, Cat. No.

- 2491.431, Rest of World: Eppendorf AG, Cat. No. 0030073.266], Matrix TallTips® [Matrix Technologies Corp., Cat. No. 7281] or LTS Tips [Rainin Instrument, LLC, Cat. No. SR-L10F, SR/SS-L250S, SR/SS-L300S]. Before using other types of pipette tips, please ensure they reach the bottom of the Nucleocuvette™ wells without getting stuck
- Solution for coating: 1 mg/ml poly-L-lysine [PLL; Sigma] dissolved in borate buffer, sterilized by filtration (as an alternative to PLL, poly-D-lysine can be used as well for cultivation over more than 3 days); 10 µg/ml laminin solution [Invitrogen, Cat. No. 23017-015]; PBS
- Poly-L-lysine (PLL) and laminin coated glass coverslips [Marienfeld; 15 mm] or PLL coated 384-well culture plates
- Dissection solution: 500 ml HBSS [Lonza; Cat. No. 10-508F], 5 ml penicillin/streptomycin [Lonza; Cat. No. 17-602E], 5 ml 1 M MgCl₂, 3.5 ml 1 M Hepes (pH 7.3) and 5 ml 200 mM L-glutamine; sterilized by filtration and pre-cooled on ice before use
- 1 mg/ml trypsin [Sigma; Cat. No. T4799] in calcium and magnesium-free HBSS [Lonza; Cat. No. 10-543F] or Trypsin/EDTA mixture [Lonza; Cat. No. 17-160; used as 1x solution]; HBSS [Lonza; Cat. No. 10-508F] for washing

- Culture medium (for embryonic neurons): PNGM™ BulletKit™ (Lonza; Cat. No. CC-4461) including PNB™ Basal Medium and PNGM™ SingleQuot™ Supplements (GA-1000, final concentration 0.1%; NSF-1, final concentration 2%; L-glutamine, final concentration 2 mM). The medium is supposed to be serum free. On occasion 5% horse serum or FCS serum can be used transiently during plating of the cells
- Culture medium (for adult neurons): PNB™-A BulletKit™ (Lonza; Cat. No. CC-4512; for adult neurons) including PNB™ Basal Medium and PNGM™-A SingleQuot™ Supplements (GA-1000, final concentration 0.1%; NSF-1, final concentration 2%; L-glutamine, final concentration 2 mM; additional components are included in the PNGM™-A SingleQuot™ Kit to adjust for unique growth conditions required for optimal growth and survival of adult neurons). The medium is supposed to be serum free. On occasion 5% horse serum or FCS serum can be used transiently during plating of the cells. Optionally 5 µM Ara C [EMD Calbiochem; Cat. No. 251010] may be used 24 hours after plating to inhibit the proliferation of glial cells, which are more abundant in preparations from postnatal brains
- Recovery medium (optional): In case of high mortality you may use a low calcium medium, e.g. RPMI [Lonza; Cat. No. 12-167F], for the transfer from the cuvette into the culture plate (see 2.15)
- Pre-equilibrate appropriate volume of culture medium to 37°C, 5% CO₂ (120 µl per sample)
- Appropriate number of cells (2.5 x 10⁵ cells per sample)

1. Pre Nucleofection™

Note

This protocol only gives an outline for the isolation and culture of primary mammalian neurons. Please refer to more detailed protocols in the literature before starting the experiments. A selection of references is given at the end of this document.

Coating of 96-well culture plates

- 1.1 Add sufficient volume of poly-L-lysine solution to each well to cover the bottom surface
- 1.2 Incubate in a humidified 37°C/5% CO₂ incubator overnight
- 1.3 Wash 2 x with sterile water and dry
- 1.4 Fill each dish with culture medium and return to the incubator for at least 12 hours and up to 2 weeks

Preparation of coverslips (optional)

Put glass coverslips into a rack and boil in 100% ethanol (p.A.) for 5 minutes

- 1.5 Dry for 5 minutes under a laminar flow and autoclave
- 1.6 Place coverslips into an appropriate culture dish (e.g. one slide per well of 12-well plate)
- 1.7 Add 400 µl poly-L-lysine solution and incubate in a humidified 37°C/5% CO₂ incubator overnight

- 1.8 Wash 2 x with sterile water and dry
- 1.9 Incubate coverslips in 400 µl laminin solution in a humidified 37°C/5% CO₂ incubator over night
- 1.10 Wash 2 x with sterile PBS. For more details please refer to Zeitelhofer M et al. 2007 (see reference list at the end of this document)

Preparation of dissociated hippocampal or cortical neurons for Nucleofection™

- 1.11 Separate heads from rat embryos (E17-18) or early postnatal rats (P0-2)
- 1.12 Dissect brains from the skull and transfer them into a Petri dish with pre-cooled dissection solution
- 1.13 Cut brains along midline and extract hippocampi or cortices
- 1.14 Store hippocampi or cortices in at least 10 ml dissection solution in Falcon tubes on ice
- 1.15 Centrifuge at 80xg for 5 minutes and carefully remove supernatant (alternatively, if experienced, remove dissection solution by very careful decanting)
- 1.16 Add 1.5 ml trypsin solution and incubate for 10–20 minutes at 37°C
- 1.17 After trypsinization, centrifuge at 80xg for 5 minutes and carefully remove supernatant (alternatively, if experienced, remove dissection solution by very careful decanting)
- 1.18 Wash two times with HBSS
- 1.19 After the second wash, add 1.5 ml of culture medium, prewarmed to 37°C
- 1.20 Triturate about 20–30 x with a fire-polished Pasteur pipette until all pieces of tissue are homogeneously dispersed
- 1.21 Triturate a second time for exactly 1 minute with a fire-polished Pasteur pipette
- 1.22 Add 5 ml of culture medium and count cells
- 1.23 Continue at step 2.1 of the Nucleofection™ protocol

2. Nucleofection™

One Nucleofection™ sample contains

- 2.5 x 10⁵ cells
- 0.1–0.6 µg plasmid DNA (in 1–2 µl H₂O or TE) or 0.4 µg pmaxGFP™ vector or 30–300nM siRNA (0.6–6 pmol/sample)
- 20 µl P3 primary cell HT Nucleofector™ solutions

Note

The volumes and cell numbers indicated below refer to the exact numbers required for a Nucleofection™ experiment. Please include sufficient extra volume and cells when setting up your pipetting scheme to account for possible losses during pipetting or small discrepancies in pipetted volumes (which may arise from inexactly calibrated pipettes or loose pipette tips).

Note

Ideally, establish plating densities in 96-well culture plates before performing a Nucleofection™ experiment. Cell numbers and volumes can be adapted such that fewer cells are transferred or duplicate plates can be seeded. When transfecting lower cell numbers you will likely need to transfer a larger volume of resuspended cells. As a guideline, number of transferred cells should be in the range of 4×10^4 to 8×10^4 cells per 384-well ($125\text{--}250$ cells/mm²). As transfected neural cells can quickly form aggregates it is important to transfer cells to culture plate as quickly as possible after addition of medium.

- 2.1 Please make sure that the entire supplement is added to the Nucleofector™ solution
- 2.2 Start HT Nucleofector™ software, verify device connection and upload experimental parameter file (for details please refer to the HT Nucleofector™ manuals)
- Select appropriate HT Nucleofector™ program. Please try all 7 Nucleofector™ programs (CA-138-AA, CL-133-AA, CU-110-AA, DC-100-AA, DR-104-AA, DR-114-AA and EM-110-AA) initially to determine the optimal one for your specific neuron type
- 2.3 Prepare culture dishes with PLL/laminin-coated cover slips or PLL-coated 96-well culture plates by filling appropriate number of dishes/wells with desired volume of culture medium (recommendation 160 µl per well for 384-well plates; see notes above) and pre-incubate/equilibrate plates in a humidified 37°C/5% CO₂ incubator
- 2.4 Prepare 0.1–0.6 µg plasmid DNA or 0.4 µg pmaxGFP™ vector. For siRNA experiments we recommend to start using 30 nM–300 nM siRNA (0.6–6 pmol/sample)
- 2.5 Centrifuge the required number of cells (2.5×10^5 cells per sample) at 80xg for 10 minutes at room temperature
- 2.6 Resuspend the cell pellet carefully in 20 µl room temperature HT Nucleofector™ solution per sample

A: One or several substrates (DNAs or RNAs) in multiples

- Prepare mastermixes by dividing cell suspension according to number of substrates
- Add required amount of substrates to each aliquot (max. 2 µl per sample)
- Transfer 20 µl of mastermixes into the wells of the 384-well Nucleocuvette™ plates

B: Multiple substrates (e.g. library transfection)

- Pipette 20 µl of cell suspension into each well of a sterile U-bottom 384-well microtiter plate
- Add 2 µl substrates (maximum) to each well
- Transfer 20 µl of cells with substrates into the wells of the 384-well Nucleocuvette™ plates

Note

It is advisable to pre-dispense each cell suspension into a sterile round-bottom 384-well plate or to pipet from a pipetting reservoir for multi-channel pipettes. Use a liquid handling system or at least a multi-channel pipette with suitable pipette tips. As leaving cells in HT Nucleofector™ solution for extended periods of time may lead to reduced transfection efficiency and viability it is important to work as quickly as possible. Avoid air bubbles while pipetting.

- 2.7 Briefly shake the 384-well Nucleocuvette™ plate with an appropriate microtiter plate shaker to make sure the sample covers the bottom and the sides of the wells without air bubbles. Alternatively thoroughly tap the 384-well Nucleocuvette™ plate
- 2.8 Place 384-well Nucleocuvette™ plate with closed lid onto the carousel of the plate handler of the HT Nucleofector™. Well “A1” must be in upper left position
- 2.9 Start Nucleofection™ process clicking “Start” in the HT Nucleofector™ software (for details please refer to the HT Nucleofector™ manuals)
- 2.10 After run completion, carefully remove the 384-well Nucleocuvette™ plate from the carousel
- 2.11 Resuspend cells with desired volume of pre-warmed culture medium (maximum cuvette volume 60 µl). Mix cells by gently pipetting up and down two to three times. Recommendation for 384-well plates: Resuspend cells in 40 µl of pre-warmed media*
- 2.12 Plate desired amount of cells in culture system of your choice. Recommendation for 384-well plates: Transfer 6 µl of resuspended cells to 54 µl pre-warmed media

Optional (in case of very high mortality)

- 2.13 If very high mortality is observed, a recovery step can be useful: immediately after Nucleofection™, add 100–300 µl pre-equilibrated recovery medium to the cuvette (instead of the standard culture media) and gently transfer it to a reaction tube
- 2.14 Place the cell suspension in incubator for 5–10 minutes (=“Recovery Step”)
- 2.15 Transfer the sample into the prepared culture dish with the coated coverslip and continue at 3.1 of the protocol

3. Post Nucleofection™

- 3.1 Incubate the cells in humidified 37°C/5% CO₂ incubator until analysis
- 3.2 Optionally (in case of much debris): Carefully replace half of the medium with fresh culture medium after 2–4 hours
- 3.3 Optionally (in case of much debris): Carefully replace the medium completely with fresh culture medium after 24 hours
- 3.4 After 24–48 hours of incubation viability of cells can be evaluated by proportion of cells attached to the cover slips. Depending on the gene, expression is often detectable after 6–8 hours and can be observed up to 12–14 days after Nucleofection™
- 3.5 Replace half of the culture medium with fresh medium once a week

Additional information

Up-to-date List of all Nucleofector™ references

www.lonza.com/nucleofection-citations

Technical assistance and scientific support

USA/Canada

Tel 800 521 0390 (toll-free)

Fax 301 845 8338

scientific.support@lonza.com

Europe and Rest of World

Tel +49 221 99199 400

Fax +49 221 99199 499

scientific.support.eu@lonza.com

www.lonza.com

Lonza Cologne GmbH—50829 Cologne, Germany

Please note that the Amata™ Nucleofector™ technology is not intended to be used for diagnostic purposes or for testing or treatment in humans. The Nucleofector™ technology, comprising Nucleofection™ process, Nucleofector™ device, Nucleofector™ solutions, Nucleofector™ 96-well Shuttle™ system and 96-well Nucleocuvette™ plates and modules is covered by patent and/or patent-pending rights owned by Lonza Cologne GmbH. Amata, Nucleofector, Nucleofection, 96-well Shuttle, Nucleocuvette, maxGFP, Clonetics, Reagent Pack, BEGM, MEGM, PrEGM, SAGM and BulletKit are either registered trademarks or trademarks of the Lonza Group or its affiliates. TallTips are a registered trademark of Matrix Technologies Corporation. Other product and company names mentioned herein are the trademarks of their respective owners.

This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com. The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242. The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtainment of such license. No statement is intended or should be construed as a recommendation to infringe any existing patent.

© Copyright 2009, Lonza Cologne GmbH. All rights reserved—D5SP-9012 2011-08